MA
NTRP

MYDA Advisors’s Neurotrope, Inc. Common NTRP Stock Holding History

MYDA Advisors’s Portfolio NTRP Stock Details NTRP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-76,909
Closed -$89K – 173
2020
Q2 		$89K Buy
+76,909
New +$96.3K 0.05% 94
2019
Q3 		– Sell
-76,901
Closed -$617K – 160
2019
Q2 		$617K Sell
76,901
-49,784
-39% -$335K 0.21% 66
2019
Q1 		$690K Buy
+126,685
New +$545K 0.35% 62

Other funds holding NTRP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AFAS
Acorn Financial Advisory Services Reston, Virginia $753M AUM 36.94% 1-Year Est. Return
PTP
Platform Technology Partners New York $519M AUM 20% 1-Year Est. Return
OGC
One68 Global Capital New York $30.9M AUM
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MYDA Advisors's NTRP Position: Q3 2020 in Review

MYDA Advisors sold out of Neurotrope, Inc. Common (NTRP) in Q3 2020, closing a stake of 76,909 shares — an estimated $89K sold.

MYDA Advisors first reported a position in NTRP in Q1 2019 and held it in 3 quarters. The position peaked at $690K in Q1 2019. 34 funds tracked by Wall St. Rank hold NTRP as of Q3 2020.

  • MYDA Advisors reported no remaining Neurotrope, Inc. Common position as of Q3 2020 after selling out during the quarter.
  • MYDA Advisors sold 76,909 Neurotrope, Inc. Common shares in Q3 2020, an estimated $89K.
  • MYDA Advisors first reported a position in Neurotrope, Inc. Common in Q1 2019 and held it in 3 quarters.
  • MYDA Advisors's Neurotrope, Inc. Common position peaked at $690K in Q1 2019.
  • 34 funds tracked by Wall St. Rank held Neurotrope, Inc. Common as of Q3 2020.

Based on MYDA Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.